AG
SGMO

Algert Global’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Algert Global’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-112,740
Closed -$467K – 1324
2022
Q2 		$467K Buy
112,740
+3,590
+3% +$15.5K 0.04% 782
2022
Q1 		$634K Buy
+109,150
New +$649K 0.04% 726
2015
Q3 		– Sell
-11,940
Closed -$132K – 342
2015
Q2 		$132K Buy
+11,940
New +$154K 0.07% 297

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Algert Global's SGMO Position: Q3 2022 in Review

Algert Global sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2022, closing a stake of 112,740 shares — an estimated $467K sold.

Algert Global first reported a position in SGMO in Q2 2015 and held it in 3 quarters. The position peaked at $634K in Q1 2022. 197 funds tracked by Wall St. Rank hold SGMO as of Q3 2022.

  • Algert Global reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2022 after selling out during the quarter.
  • Algert Global sold 112,740 SANGAMO THERAPEUTICS INC shares in Q3 2022, an estimated $467K.
  • Algert Global first reported a position in SANGAMO THERAPEUTICS INC in Q2 2015 and held it in 3 quarters.
  • Algert Global's SANGAMO THERAPEUTICS INC position peaked at $634K in Q1 2022.
  • 197 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2022.

Based on Algert Global's 13F filing for Q3 2022, filed 15 Nov 2022.